Blue Jet Healthcare Faces Mixed Financial Performance Amidst Growth and Challenges

Blue Jet Healthcare has recently undergone a financial trend adjustment, reflecting a flat performance for the quarter ending September 2025. The company's financial score has notably declined, indicating challenges despite some positive metrics.
On the positive side, Blue Jet Healthcare reported net sales of Rs 520.24 crore over the last six months, showcasing a growth rate of 40.17%. Additionally, the profit after tax (PAT) for the same period reached Rs 143.31 crore, marking a growth of 49.08%. The return on capital employed (ROCE) stands at a robust 36.49%, and the dividend per share (DPS) is at its highest level of Rs 1.20.

However, the company faces significant hurdles. The quarterly PAT has fallen to Rs 52.14 crore, a decrease of 41.8% compared to the previous four-quarter average. Other concerning metrics include the lowest operating cash flow of Rs 45.76 crore and a debtor turnover ratio of just 0.38 times. Furthermore, net sales for the quarter were recorded at Rs 165.48 crore, the lowest in recent times.

In terms of stock performance, Blue Jet Healthcare has shown varied returns compared to the Sensex, with a year-to-date return of 7.02% against the Sensex's 6.81%. Over the past year, the stock has outperformed the Sensex, returning 29.16% compared to the index's 5.94%. This context highlights the company's mixed performance amidst broader market trends.